التفاصيل البيبلوغرافية
| العنوان: |
NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. |
| المؤلفون: |
Novakova, L., Axelsson, M., Malmeström, C., Zetterberg, H., Blennow, K., Svenningsson, A., Lycke, J. |
| المصدر: |
Multiple Sclerosis & Related Disorders; Nov2020, Vol. 46, pN.PAG-N.PAG, 1p |
| مستخلص: |
• All patients with ongoing disease activity (relapse or new lesions on MRI) had increased NFL or CXCL13. • The same proportion of patients with relapsing-remitting and progressive MS without ongoing disease activity had increased either NFL or CXCL13 or both biomarkers. • These markers might be more sensitive to disease activity than clinical and MRI measures. • At a later stage of the disease, NFL and CXCL13 could not predict disease activity or disability. Cerebrospinal fluid (CSF) levels of neurofilament light (NFL), a biomarker of axonal damage, and CXCL13, a chemokine involved in B-cell regulation, are both associated with disease activity in multiple sclerosis (MS). To explore the potential of NFL and CXCL13 to detect residual disease activity in patients with no signs of clinical or ongoing radiological activity and to study the clinical relevance of such activity. NFL and CXCL13 concentrations were determined with ELISA in CSF obtained from 90 relapsing-remitting (RR) MS and 47 Progressive (Pr) MS (including primary and secondary PrMS) at baseline and after 12 months of follow-up. The patients were assessed at baseline, before initiating or switching disease modifying therapy (DMT) and again after 12 and 27 months of follow-up. All patients with ongoing disease activity (relapse or contrast-enhancing lesions on MRI) had increased NFL or CXCL13. The proportion of RRMS and PrMS patients without ongoing disease activity with elevation of either NFL or CXCL13 (residual disease activity) was 39% and 50%, respectively, and both were increased in 11% and 16%, respectively. The treatment with DMTs decreased the proportion with residual disease activity in both RRMS and PrMS significantly. We could not show any significant association between residual disease activity and clinical or MRI measures at 12 or 27 months of follow-up. Although most of this real-world study population had been treated with second-line DMTs and achieved clinical and radiological stability, a significant proportion of patients still displayed increased CSF levels of both NFL and CXCL13, indicating residual disease activity. Thus, these markers seemed considerably more sensitive to disease activity than clinical and MRI measures. However, the long-term clinical significance of such activity remains to be determined. [ABSTRACT FROM AUTHOR] |
|
Copyright of Multiple Sclerosis & Related Disorders is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
